Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Allopurinol
Drug ID BADD_D00076
Description Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Indications and Usage For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.
Marketing Status Prescription; Discontinued
ATC Code M04AA01
DrugBank ID DB00437
KEGG ID D00224
MeSH ID D000493
PubChem ID 135401907
TTD Drug ID D04KYY
NDC Product Code 50268-063; 49711-0113; 16714-041; 0603-2116; 14445-001; 69967-008; 55700-879; 50090-4662; 23155-694; 53489-156; 0591-5544; 0904-7041; 0378-0181; 55700-935; 66267-665; 61919-748; 50090-5194; 67457-187; 51079-206; 63739-796; 43063-976; 68083-380; 23155-693; 70518-1678; 71335-0112; 17351-0041; 55700-540; 67296-1265; 71610-253; 63629-2113; 51079-205; 50268-064; 29300-350; 68071-2660; 70934-072; 55700-947; 55154-5534; 50090-0044; 70934-389; 61919-471; 55111-730; 68071-1805; 71610-197; 70518-3289; 70710-1210; 63629-1781; 58118-1156; 67296-1314; 49452-0008; 70518-1806; 65015-606; 16729-135; 0904-6571; 63552-151; 70771-1127; 55154-2338; 62584-988; 70199-016; 70710-1209; 43353-088; 55154-7892; 16729-134; 0615-8385; 0591-5543; 68108-0212; 71205-208; 63629-8020; 43063-975; 71335-0467; 70771-1126; 68071-2616; 63187-240; 53002-4821; 36974-0018; 50090-2544; 69967-009; 70934-504; 63629-7908; 0615-8321; 51927-0070; 71610-064; 63629-2111; 50090-5168; 71610-194; 60760-134; 53002-4820; 65219-380; 70934-295; 65977-0124; 43063-793; 70199-015; 67457-978; 71610-231; 67544-736; 50090-3760; 43063-079; 71205-377; 62584-713; 71205-049; 50090-4663; 63629-1675; 63552-150; 0378-0137; 16714-042; 16714-577; 55154-7981; 16714-576; 43063-935; 29300-349; 70934-209; 70518-0451; 55289-010; 43353-186; 0603-2115; 55154-5454; 43063-774; 71335-1656; 55111-729; 60760-139; 0904-6572; 63629-2112; 70934-681; 43063-934; 50090-3758; 63739-410; 57451-1166; 60429-180; 66064-2100; 51927-1915; 66267-224; 68788-7542; 53489-157; 63187-463; 70518-1573; 68788-7383
Synonyms Allopurinol | Uribenz | Allopurin | Allorin | Allpargin | Allural | Pan Quimica | Apulonga | Apurin | Atisuril | Bleminol | Caplenal | Capurate | Cellidrin | Embarin | Suspendol | Foligan | Hamarin | Lopurin | Lysuron | Jenapurinol | Milurit | Milurite | Novopurol | Uripurinol | Urosin | Urtias | Xanthomax | Uridocid | Xanturic | Zygout | Zyloprim | Zyloric | Pureduct | Purinol | Progout | Remid | Rimapurinol | Roucol | Tipuric | Allohexal | Allohexan | Alloprin
Chemical Information
Molecular Formula C5H4N4O
CAS Registry Number 315-30-0
SMILES C1=NNC2=C1C(=O)NC=N2
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Delirium19.13.02.0010.000395%
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.0020.001516%Not Available
Dermatitis allergic10.01.03.014; 23.03.04.0030.000198%Not Available
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Dermatitis bullous23.03.01.0020.000923%
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.001186%
Diabetes mellitus05.06.01.001; 14.06.01.0010.000527%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.000264%Not Available
Dilatation ventricular02.04.02.0260.000132%Not Available
Discomfort08.01.08.003--Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000034%
Diverticulum intestinal07.10.01.0020.000132%Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.000461%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dysarthria17.02.08.001; 19.19.03.001--
Dysgeusia07.14.03.001; 17.02.07.0030.000593%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.01.03.002; 22.02.01.004--
Dyspnoea exertional02.01.03.003; 22.02.01.0050.000329%Not Available
Dysuria20.02.02.0020.000329%
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Ectropion06.06.04.001; 23.07.05.0010.000264%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene